Company intelligence / Profile preview

Audion Therapeutics

Amsterdam, Netherlandsaudiontherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Audion Therapeutics has completed a Phase I/IIa trial of LY3056480, an intratympanically administered gamma-secretase inhibitor for sensorineural hearing loss. The Phase I trial with 15 patients confirmed safety and tolerability of the highest dose (250 micrograms). Some patients showed improvements in speech understanding in noisy environments, with benefits continuing during the 12-month follow-up period. The company has advanced to a multi-center Phase II efficacy study with 40 adult patients with mild to moderate SNHL in the UK, Germany, and Greece.[5][7][8]

Therapeutic areas: Neurology
Modalities: Small molecules (gamma-secretase inhibitor)
Industry: Biotech

Drug pipeline

1 asset

LY3056480

Discontinued

Partnerships

REGAIN consortium (international consortium of 7 partners)

Beyond the preview

Go deeper on Audion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Audion Therapeutics.